Friday, September 03, 2010

Site Search

Archive for the ‘ADMET Studies’ Category

TimTec Launches Division of Organic Synthesis and Medicinal Chemistry Contract Research Services

Last Updated on Saturday, 24 July 2010 04:31 Written by admin Thursday, 8 July 2010 11:39

Newark, DE, July 8, 2010 Press Release – TimTec, LLC is pleased to announce the launching of the new Division that manages Organic Synthesis and Medicinal Chemistry Contract Research Services. The emergence of the division is an evolutionarily progression for TimTecs business development. The company has been known for its expertise in organic chemistry design and supply for drug discovery for 15 years. TimTec scientists have a proven track record of providing high quality services and showing outstanding integrity to their clients.

The Head of Contract Research Services, J. C. Pelletier, PhD., has over 20 years of research experience in the US pharmaceutical industry as a hands-on medicinal chemist and project Team Leader at large companies and smaller, start-up operations. The TimTec contract research team consists of experienced, bench level scientists who have access to state of the art synthesis, analytical and quality control facilities. TimTec specialists are keenly aware of all the intricate details and chemistry challenges that go into bench-top research before a qualified lead molecule emerges.

TimTec remains flexible in delivering practical chemistry solutions molded to custom research requirements and budgets. Contract research services include, but are not limited to, flexible contracts, program management, structure-activity relationship evaluation,  lead optimization,  property optimization for ADME and PK, metabolite synthesis,  enabling technologies (parallel synthesis, multistep synthesis, analytical chemistry),  mg to kg synthesis capacity,  compound distribution, and patent application preparation assistance. The Contract Research Division puts great emphasis on speed, real-time feedback, ongoing communication, superior compound quality, and the protection of clients knowledge resources and interests. Dedication to service is matched by exceptionally competitive prices.

Contact Information:

TimTec LLC
Harmony Business Park A-301
Newark DE 19711
Tel 302 292 8500

Fax 302 292 8520

info@timtec.net

http://www.timtec.net/contract-research-services.html

About TimTec

TimTec LLC is a privately held company located in Newark Delaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds and collections, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.

Posted under ADMET Studies, Business and Investment, Drug-Like Compounds, North America, Press Releases, R & D, Research Projects  |  No Comments

TimTec’s Contract Research Services

Last Updated on Thursday, 8 July 2010 10:18 Written by Editor Thursday, 8 July 2010 03:22

High Quality Organic Synthesis and Medicinal Chemistry Contract Research Services at an Outstanding Value

TimTec brings 15 years of expertise in organic chemistry design and supply for drug discovery closer to your supplemental bench-top requirements by launching The Organic Synthesis and Medicinal Chemistry Contract Research Services Division. TimTec scientists have a proven track record of providing high quality services and showing outstanding integrity to their clients.

TimTec remains flexible in delivering practical chemistry solutions molded to custom research requirements and budgets. All Contract Research Services are delivered with an emphasis on speed, real-time feedback, ongoing communication, superior compound quality, and the protection of our clients’ knowledge resources and interests. We are dedicated to providing these services at exceptionally competitive prices.

The Head of Contract Research Services has over 20 years of research experience in the US pharmaceutical industry as a hands-on medicinal chemist  and project Team Leader at large companies and smaller, start-up operations. We are keenly aware of all the intricate details and chemistry challenges that go into bench-top research before a qualified lead molecule emerges. Your TimTec contract research team consists of experienced, bench level scientists who have access to state of the art synthesis, analytical and quality control facilities.

TimTec Contract Research Services Start with:

  • Flexible Contracts

  • Program Management

  • State of the Art Facilities

  • Structure-Activity Relationship Evaluation

  • Lead Optimization

  • Property Optimization for ADME and PK

  • Metabolite Synthesis

  • Enabling Technologies – Parallel synthesis, multistep synthesis, analytical chemistry

  • Mg to Kg Capacity

  • Compound Distribution – Solid or solution, vials or plates

  • Patent Application Preparation Assistance

Supplemental Services and Products:

Custom Synthesis
Compound Acquisition
Weighting and Plating
HTS compounds and compound collections – ActiMol Line of products


Trends in Drug Research 27th Noordwijkerhout-Camerino-Cyprus Conference Noordwijkerhout, The Netherlands, May 3 – 8, 2009

Last Updated on Thursday, 27 November 2008 10:24 Written by admin Thursday, 27 November 2008 10:24

The Symposium is sponsored by the European Federation of Medicinal Chemistry (EFMC).

The Organising and Scientific Committees cordially invite you to attend the 27 edition of this meeting on Trends in Drug Research. The interplay between molecular structure and biological activity is central to contemporary biomedical and translational research, relevant not only to structural biologists but also to diverse scientists involved in the study of bioactive compounds and signalling mediators and those working in drug discovery and development.

The scientific programme will include plenary lectures, oral communications and poster sessions. Registration will open on Sunday May 3, followed by an inaugural evening lecture and a welcome gathering.
The scientific programme ends on Thursday May 7 and the meeting will be concluded by the symposium dinner on Thursday evening. On Friday after the conference, a complimentary workshop “Virtual Screening and De Novo Design” is offered by BioSolveIT.

REGISTRATION Information and the complete SCIENTIFIC PROGRAMME is available on the SYMPOSIUM’S WEBSITE: WWW.NOORDWIJKERHOUTMEDCHEM.ORG

PROGRAMME

Opening keynote lecture

Chairman Prof. Henk TIMMERMAN (VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Chemistry’s Role In Target Identification And Validation Dr. Scott A. BILLER (NOVARTIS, Cambridge, United States)

KINASE INHIBITORS: TARGETING THE NON-ATP SITE

Chairman: Dr. Edmond DIFFERDING (UCB, Braine-l’Alleud, Belgium)

Discovery And Development of Selective, Orally Bioavailable Tyrosine Kinase Inhibitors For Targeted Treatment Of Human Cancers Prof. Stephen K. BURLEY (SGX PHARMACEUTICALS, SAN DIEGO, United States)

Non-Competitive Inhibitors of MEK1: from Discovery to the Clinic Dr. Jeffrey OHREN (PFIZER, GROTON, United States)

Allosteric Inhibition of Kinase Function Philip E. SANDERSON (MERCK, Rahway, United States)

CHEMICAL AND ENZYMATIC MODIFICATION OF THERAPEUTIC PEPTIDES AND PROTEINS TO IMPROVE THEIR MODE OF ACTION

Chairman: Dr. Stan VAN BOECKEL (ORGANON, Oss, The Netherlands)

Title to be announced
Dr. Jesper LAU (NOVO NORDISK, Maaloev, Denmark)

Sugars and Proteins
Prof. Ben DAVIS (OXFORD UNIVERSITY, Oxford, United Kingdom)

CarboCarrier(TM): a Novel Technology to Extend the Half-life of Small Proteins and Peptides Martin DE KORT (ORGANON, Oss, The Netherlands)

PROMISES IN GPCR DRUG DISCOVERY

Chairman: Prof. ROB LEURS (LEIDEN/AMSTERDAM CENTER FOR DRUG RESEARCH, Amsterdam, The Netherlands)

Structural Genomics of GPCRs; New Opportunities for Drug Discovery Chris TATE (MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge , Belgium)

GPCR Hetero-Dimerisation: Contribution to Receptor Pharmacology and Function Prof. Graeme MILLIGAN (UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

Dicovery & Development of Allosteric Modulators: Hopes and Promises Dr Emmanuel LE POUL (ADDEX PHARMA, Plan les Ouates, Switzerland)

TRANSPORTERS

Chairman: Prof. Gerhard ECKER (UNIVERSITY OF VIENNA, Vienna, Austria)

Predicting Substrate Properties for ABC-Transporter – Safety Sciences on the Molecular Level Prof. Gerhard ECKER (UNIVERSITY OF VIENNA, Vienna, Austria)

Drug Transport and Metabolism: Value of Knockout and Transgenic Mouse Models Dr. Alfred SCHINKEL (HET NEDERLANDS KANKER INSTITUUT , Amsterdam, The Netherlands)

Title to be announced
Prof. Robert FORD (THE UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

OFF-TARGET EFFECTS

Chairman: Prof. Hugo KUBINYI (Weisenheim am Sand, Germany)

GPCR Antitargets – Prediction and Prevention of Side Effects Dr. Thomas KLABUNDE (SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany)

Understanding Ion Channels Using Computational Approaches Dr. Marcel J. DE GROOT (PFIZER, Sandwich, United Kingdom)

The QSARome of the Receptorome: Development of Robust QSAR Models Capable of Predicting Compound Binding Profiles against Multiple Targets Prof. Alexander TROPSHA (UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, United States)

FRAGMENT BASED DRUG DISCOVERY

Chairman: Dr. Iwan DE ESCH (VRIJE UNIVERSITEIT AMSTERDAM, Amsterdam, The Netherlands)

Experiences in Fragment-based Lead Discovery Prof. Roderick E. HUBBARD (UNIVERSITY OF YORK, York, United Kingdom)

SPR Biosensor-Based Fragment Screening and Lead Characterization Prof. U. Helena DANIELSON (UPPSALA UNIVERSITY, Uppsala, Sweden)

Novel-Generation Kinase Inhibitors: Deep Pocket Binders by Fragment- Based Design Dr. Gerhard MÃœLLER (CSO PROTEROS FRAGMENTS GMBH, Munich/Martinsried, Germany)

ANTI-INFLAMMATORY DRUG DISCOVERY

Chairman: Robin THURMOND (JOHNSON & JOHNSON, San Diego, United States)

Histamine H4 Antagonists as Future Anti-Inflammatory Drugs Robin THURMOND (JOHNSON & JOHNSON, San Diego, United States)

JAK3 Kinase: a Molecular Target for Treatment of Inflammatory Diseases and Renal Transplant Rejection Dr. Paul S. CHANGELIAN (CHANGELIAN BIOSCIENCE, LLC, , United States)

Molecular Mechanim of Action for Chemokine and Other Anti-inflammatory Agents on 7TM Receptors Dr. Thue W. SCHWARTZ (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Complimentary Workshop on Friday: “Virtual Screening and De Novo Design” offered by BioSolveIT Late Departure – the transportation will be provided by the organisers.

http://www.LDOrganisation.com

Posted under ADMET Studies, Drug Development, Europe, Europe, Press Releases, Targeted Libraries  |  No Comments

WuXi PharmaTech Inks New Three-year Deal with Pfizer

Last Updated on Tuesday, 11 November 2008 02:55 Written by admin Tuesday, 11 November 2008 02:55

WuXi PharmaTech (NYSE: WX) has signed a new three-year CRO deal with Pfizer (NYSE: PFE) to collaborate on in vitro ADME (Absorption, Distribution, Metabolism and Excretion) services. Although WuXi has already been providing the services to Pfizer, WuXi said the new agreement “strengthens an already productive relationship.” WuXi also provides Pfizer with synthetic chemistry, parallel medicinal chemistry (PMC), and bioanalytical services.

In partnership with Pfizer, WuXi PharmaTech will establish ADME assays to provide in vitro screening services on compounds WuXi PharmaTech synthesizes for Pfizer. The goal is to improve the pharmacokinetic properties of new compounds.

The announcement did not disclose financial details of the contract.

Posted under ADMET Studies, Collaborations, Compound Libraries, Compound Screening, Drug-Like Compounds, Medicinal Chemistry, North America, Press Releases  |  No Comments

Cell-Based Assays: Innovations in Reagents, Technologies & Screening October 23 – 24, 2008

Last Updated on Thursday, 23 October 2008 12:56 Written by admin Wednesday, 22 October 2008 04:56

Cell-based assays provide one of the most valuable tools in drug discovery.  They are routinely used in target validation, HTS campaigns, structure activity relationship analyses and ADMET studies. Many factors need to be considered in designing, developing and running relevant cell based assays to progress discovery programs.  Significant advances continue to be made in assay design and cell supply processes that incorporate biologically relevant cell types and novel detection technologies. This symposium is designed to capture successful techniques and practices that enable high quality cell-based assays using commonly employed cell types such as CHO, HEK and U-2 OS, as well as the expanding application of additional cell types. The symposium will be of great interest to cell culture scientists, assay developers, screeners, medicinal chemists, ADMET and therapeutic teams.

Session Overviews:

Session 1: Cells as Reagents – Fact or Fiction?
This session will cover various aspects of the most important material used in cell-based assays: the cells. The talks will address the topics such as: how to characterize cell lines to ensure their identity? What are the impacts to the cells after transfection? What are the issues during scale up process? This session will also highlight advances in cell culture automation and material tracking system for cell-based assays.

Session 2: Assay Development – Present Realities
Topics covered include the application of BacMam virus based gene delivery in assay development, the development of high-content cellular assays, dielectric spectroscopy technology and photoprotein aqueorin based GPCR assay platforms and considerations in screening for antibody based therapeutics.

Session 3: Cell-Based Screening – The How, Why & Where
This session will include topics on the implementation of cell-based assays and screens across the discovery process focusing on the challenges, solutions and issues to consider. Presentations include experiences with high throughput screening for lead identification, profiling with cellular panels, ADME applications, and the use of high content screening in both drug discovery and to probe complex cellular systems.

Session 4: Cell-Based Assays – Emerging Trends
The topics in this session will address emerging trends in supply of cells that attempts to bridge the gap between traditional target based in vitro assays and in vivo measurements. The presentations will highlight potential applications of cells to build model systems that can offer the combined benefits of traditional in vitro and ex vivo approaches. These emerging technologies and methodologies hold the promise of addressing a major gap in using target based approaches to discover new biological tools and drugs and will challenge the supply of cell reagents.

http://www.sbsonline.com/

Posted under ADMET Studies, Cell-based Assays, Genomics & Pharmacogenomics, HT Screening, Medicinal Chemistry, North America, Press Releases, USA and Canada  |  No Comments